The European Commission (EC) has approved the paediatric licence variation of Zonegran® (zonisamide), a novel anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED [1]. Zonisamide is now indicated as an adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adolescents and children aged six years and above in addition to its existing license in adult patients [1]. Epilepsy is a common condition in children and adolescents, affecting around 10...
No comments:
Post a Comment